Veracyte Inc
NASDAQ:VCYT

Watchlist Manager
Veracyte Inc Logo
Veracyte Inc
NASDAQ:VCYT
Watchlist
Price: 27.16 USD -0.88% Market Closed
Market Cap: 2.1B USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one VCYT stock under the Base Case scenario is 24.78 USD. Compared to the current market price of 27.16 USD, Veracyte Inc is Overvalued by 9%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VCYT Relative Value
Base Case
24.78 USD
Overvaluation 9%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

4.7
P/S
P/S
Price to Sales
4.7
vs History
85
vs Industry
57
Median 3Y
5.6
Median 5Y
6.3
Industry
6.9
Forward
4.2
More Details
87.5
P/E
P/E
Price to Earnings
87.5
vs History
7
vs Industry
1
Median 3Y
-32.6
Median 5Y
-43.5
Industry
22.9
Forward
42.1
More Details
28.1
P/OCF
P/OCF
Price to OCF
28.1
vs History
55
vs Industry
5
Median 3Y
45.6
Median 5Y
35
Industry
19.7
More Details
33.1
P/FCFE
P/FCFE
Price to FCFE
33.1
vs History
41
vs Industry
5
Median 3Y
47.1
Median 5Y
-57.1
Industry
23.5
More Details
1.8
P/B
P/B
Price to Book Value
1.8
vs History
60
vs Industry
39
Median 3Y
1.7
Median 5Y
2
Industry
2.5
More Details
4.1
EV/S
EV/S
Enterprise Value to Sales
4.1
vs History
87
vs Industry
51
Median 3Y
5
Median 5Y
5.6
Industry
7.4
Forward
3.6
More Details
6.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
6.1
vs History
85
vs Industry
47
Median 3Y
7.5
Median 5Y
8.3
Industry
9.1
More Details
42.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
42.4
vs History
31
vs Industry
2
Median 3Y
46.8
Median 5Y
-56
Industry
3.8
Forward
16.3
More Details
93.4
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
93.4
vs History
17
vs Industry
1
Median 3Y
-36.9
Median 5Y
-45.4
Industry
3.8
Forward
37.2
More Details
24.3
EV/OCF
EV/OCF
Enterprise Value to OCF
24.3
vs History
55
vs Industry
5
Median 3Y
40.7
Median 5Y
30.3
Industry
4.9
More Details
28.6
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
28.6
vs History
41
vs Industry
4
Median 3Y
42.2
Median 5Y
-61.1
Industry
3.5
More Details
1.8
EV/IC
EV/IC
Enterprise Value to IC
1.8
vs History
60
vs Industry
44
Median 3Y
1.7
Median 5Y
2
Industry
4.6
More Details

Multiples Across Competitors

VCYT Competitors Multiples
Veracyte Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Veracyte Inc
NASDAQ:VCYT
2.1B USD 4.7 87.5 42.4 93.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 873 287.2 -165 747.6 -201 270.4 -198 973.6
US
Abbvie Inc
NYSE:ABBV
323.7B USD 5.6 77.9 14.9 22
US
Amgen Inc
NASDAQ:AMGN
146.1B USD 4.3 24.6 13.5 22.2
US
Gilead Sciences Inc
NASDAQ:GILD
133.7B USD 4.7 22.4 9.8 13.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112B USD 10.1 -113.3 24 25.2
US
Epizyme Inc
F:EPE
94.1B EUR 2 020.1 -515.5 -561.3 -546.4
AU
CSL Ltd
ASX:CSL
119.3B AUD 5.1 28.2 17.4 21.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
63.7B USD 4.5 14.1 12.7 14.3
US
Seagen Inc
F:SGT
39.3B EUR 19.5 -59.7 -64.3 -58
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
37.8B USD 16.1 -140.1 -625.8 -313.6
P/S Multiple
Revenue Growth P/S to Growth
US
Veracyte Inc
NASDAQ:VCYT
Average P/S: 3 170 489.3
4.7
11%
0.4
FR
Pharnext SCA
OTC:PNEXF
34 873 287.2
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.6
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.3
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.7
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.1
10%
1
US
E
Epizyme Inc
F:EPE
2 020.1
N/A N/A
AU
CSL Ltd
ASX:CSL
5.1
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.5
5%
0.9
US
S
Seagen Inc
F:SGT
19.5
30%
0.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.1
29%
0.6
P/E Multiple
Earnings Growth PEG
US
Veracyte Inc
NASDAQ:VCYT
Average P/E: 42.5
87.5
71%
1.2
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -165 747.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
77.9
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
24.6
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
22.4
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -113.3 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -515.5 N/A N/A
AU
CSL Ltd
ASX:CSL
28.2
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.1
7%
2
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -140.1 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Veracyte Inc
NASDAQ:VCYT
Average EV/EBITDA: 19.2
42.4
50%
0.8
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -201 270.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.9
13%
1.1
US
Amgen Inc
NASDAQ:AMGN
13.5
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
9.8
6%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -561.3 N/A N/A
AU
CSL Ltd
ASX:CSL
17.4
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.7
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.3 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -625.8 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Veracyte Inc
NASDAQ:VCYT
Average EV/EBIT: 30.3
93.4
81%
1.2
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -198 973.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
22.2
31%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.5
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.2
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -546.4 N/A N/A
AU
CSL Ltd
ASX:CSL
21.8
14%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.3
13%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -58 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -313.6 N/A N/A

See Also

Summary
VCYT intrinsic value, competitors valuation, and company profile.
DCF Valuation
VCYT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
VCYT stock valuation using valuation multiples.
Wall Street Estimates
VCYT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
VCYT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 257,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.